AKT1 and HIV infectious disease: For instance, combining inhibitors of AKT1 and TP53 with monoclonal antibodies targeting immune checkpoints could synergistically enhance the immune response and prevent HIV latency, which is a significant hurdle in the treatment of HIV infection.